Physician profile
Eric A Comsti
NPI 1598723827
$2,228.53
in general payments reported to CMS, 2019-2025
30 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $148 · 2021: $365 · 2022: $477 · 2023: $341 · 2024: $315 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $414.86 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $224.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $212.40 | 2019-2025 | Mounjaro, Amyvid, Kisunla |
| Novartis Pharmaceuticals Corporation | $199.20 | 2019-2024 | |
| Pfizer INC. | $195.78 | 2019-2024 | |
| Novo Nordisk INC | $114.34 | 2019-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $112.66 | 2021-2025 | |
| Eisai INC. | $86.43 | 2022-2025 | |
| Amgen INC. | $68.75 | 2022 | |
| Dexcom, INC. | $62.56 | 2021-2023 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $49.79 | 2021-2022 | |
| Astellas Pharma US INC | $43.76 | 2021-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $41.44 | 2019-2020 | |
| Boston Scientific Corporation | $41.43 | 2024 | Watchman Access System |
| Exact Sciences Corporation | $39.34 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.63 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.96 | 2024 | Xifaxan |
| Philips North America LLC | $27.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.34 | 2021-2023 | |
| Abbott Laboratories | $25.98 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $25.72 | 2022 | |
| Merck Sharp & Dohme LLC | $22.88 | 2019 | |
| Csl Behring | $21.76 | 2025 | Andembry |
| W. L. Gore & Associates, INC. | $20.09 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Viatris Specialty LLC | $18.23 | 2025 | Yupelri |
| Corcept Therapeutics | $15.94 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $15.59 | 2025 | Gemtesa |
| Bausch Health US, LLC | $15.00 | 2020 | |
| Amarin Pharma, INC. | $14.98 | 2019 | |
| Mylan Specialty L.P. | $13.40 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Comsti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.